Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $50.9 million.

  • Harmony Biosciences Holdings' Net Income towards Common Stockholders rose 1035.3% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 million, marking a year-over-year increase of 4438.4%. This contributed to the annual value of $117.5 million for FY2024, which is 881.62% down from last year.
  • Harmony Biosciences Holdings' Net Income towards Common Stockholders amounted to $50.9 million in Q3 2025, which was up 1035.3% from $39.8 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Net Income towards Common Stockholders peaked at $87.9 million during Q3 2022, and registered a low of -$9.6 million during Q3 2021.
  • In the last 5 years, Harmony Biosciences Holdings' Net Income towards Common Stockholders had a median value of $29.5 million in 2023 and averaged $30.8 million.
  • Within the past 5 years, the most significant YoY rise in Harmony Biosciences Holdings' Net Income towards Common Stockholders was 1102019.23% (2021), while the steepest drop was 13440.55% (2021).
  • Over the past 5 years, Harmony Biosciences Holdings' Net Income towards Common Stockholders (Quarter) stood at $22.7 million in 2021, then skyrocketed by 113.56% to $48.5 million in 2022, then plummeted by 72.81% to $13.2 million in 2023, then soared by 62.84% to $21.5 million in 2024, then surged by 136.86% to $50.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at $50.9 million for Q3 2025, versus $39.8 million for Q2 2025 and $45.6 million for Q1 2025.